LenioBio Receives EUR3.7M in EU4Health Funding

The project will focus on further development of the cell-free protein expression system, ALiCE®, as an innovative, rapid and on-demand medicine manufacturing technology with strategic value for Europe, fitting into the mission of HERA. The project has been awarded a grant of EUR 3.7M and commenced on 1st July 2025, continuing until late 2027. 

Read More - Gamefound acquires Indiegogo

This EU4Health action contributes to the European Union’s strategic objective to strengthen the availability, accessibility, and affordability of essential medicines. By supporting the development of innovative manufacturing processes, HERA aims to enable more efficient, cost-effective, scalable, sustainable, and environmentally cleaner production of medicines. 

LenioBio will contribute with a project titled “Innovative protein medicine biomanufacturing with Continuous-Modular ALiCE”, where key goals for the project include: 

• Scaling ALiCE® lysate production by optimising process yields, increasing batch size and transitioning to continuous manufacturing 
• Expanding ALiCE® capabilities for targeted classes of protein medicines such as vaccines, multispecific antibodies and growth factors by engineering new functionalities and demonstrating modular protein production methods at scale 
• Laying the groundwork for GMP-grade lysate production by establishing analytical qualifications, quality systems, and regulatory filing package 

 “This grant is another significant milestone for LenioBio. It enables us to scale our platform and broadens its application for medicine production, providing a future proof solution for the agile production of novel and complex proteins.” said André Goerke, CEO of LenioBio. 

Read More - Trovata Acquires ATOM